Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,551Price:$17.55
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,296Price:$18.62
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,153Price:$17.84
-
Feb 27, 2024 (filed on Feb 28, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-34,070Price:$20.11
-
Feb 27, 2024 (filed on Feb 28, 2024)Insider Name:Jaen Juan C.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-23,132Price:$20.10
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,555Price:$20.07
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Jaen Juan C.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,900Price:$20.06
-
Feb 07, 2024 (filed on Feb 07, 2024)Insider Name:Mercier JohannaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Gilead Sciences, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,238,095Price:$21.00
-
Jan 23, 2024 (filed on Feb 23, 2024)Insider Name:Goeltz II Robert C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,000Price:--
Filings by filing date
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,551Price:$17.55
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,296Price:$18.62
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,153Price:$17.84
-
Feb 27, 2024 (filed on Feb 28, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-34,070Price:$20.11
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Jarrett JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-24,555Price:$20.07
-
Feb 27, 2024 (filed on Feb 28, 2024)Insider Name:Jaen Juan C.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-23,132Price:$20.10
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Jaen Juan C.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,900Price:$20.06
-
Jan 23, 2024 (filed on Feb 23, 2024)Insider Name:Goeltz II Robert C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:22,000Price:--
-
Feb 07, 2024 (filed on Feb 07, 2024)Insider Name:Mercier JohannaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 29, 2024 (filed on Jan 31, 2024)Insider Name:Gilead Sciences, Inc.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,238,095Price:$21.00
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3928 Point Eden Way HAYWARD CA 94545-3719 |
Tel: | N/A |
Website: | https://arcusbio.com |
IR: | See website |
Key People | ||
Terry J. Rosen Chairman of the Board, Chief Executive Officer, Co-Founder | Juan Carlos Jaen President, Co-Founder | Robert C. Goeltz Chief Financial Officer |
Jennifer A. Jarrett Chief Operating Officer | Alexander Azoy Chief Accounting Officer | Carolyn Tang General Counsel | Dimitry S.A. Nuyten Chief Medical Officer |
Business Overview |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Arcus Biosciences Inc revenues increased 4% to $117M. Net loss increased 15% to $307M. Revenues reflect License and development services revenue segment increase of 8% to $80M. Higher net loss reflects Research and development - Balancing val increase of 20% to $305M (expense), General and administrative - Balancing increase of 10% to $79M (expense). |
Employees: | 577 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $650.77M as of Dec 31, 2023 |
Annual revenue (TTM): | $117.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$332.00M as of Dec 31, 2023 |
Net annual income (TTM): | -$307.00M as of Dec 31, 2023 |
Free cash flow (TTM): | -$330.00M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 90,952,836 as of Apr 9, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |